BOUNDLESS BIO INC (BOLD) Fundamental Analysis & Valuation

NASDAQ:BOLD • US10170A1007

Current stock price

1.47 USD
+0.02 (+1.38%)
Last:

This BOLD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BOLD Profitability Analysis

1.1 Basic Checks

  • In the past year BOLD has reported negative net income.
  • In the past year BOLD has reported a negative cash flow from operations.
  • In the past 5 years BOLD always reported negative net income.
  • BOLD had a negative operating cash flow in each of the past 5 years.
BOLD Yearly Net Income VS EBIT VS OCF VS FCFBOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -37.05%, BOLD perfoms like the industry average, outperforming 57.67% of the companies in the same industry.
  • BOLD has a Return On Equity (-58.99%) which is in line with its industry peers.
Industry RankSector Rank
ROA -37.05%
ROE -58.99%
ROIC N/A
ROA(3y)-35.59%
ROA(5y)-37.74%
ROE(3y)-47.8%
ROE(5y)-47.13%
ROIC(3y)N/A
ROIC(5y)N/A
BOLD Yearly ROA, ROE, ROICBOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • BOLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLD Yearly Profit, Operating, Gross MarginsBOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BOLD Health Analysis

2.1 Basic Checks

  • BOLD has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for BOLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BOLD Yearly Shares OutstandingBOLD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 5M 10M 15M 20M
BOLD Yearly Total Debt VS Total AssetsBOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -2.57, we must say that BOLD is in the distress zone and has some risk of bankruptcy.
  • BOLD has a Altman-Z score of -2.57. This is comparable to the rest of the industry: BOLD outperforms 46.60% of its industry peers.
  • BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.57
ROIC/WACCN/A
WACCN/A
BOLD Yearly LT Debt VS Equity VS FCFBOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 8.74 indicates that BOLD has no problem at all paying its short term obligations.
  • BOLD has a better Current ratio (8.74) than 75.15% of its industry peers.
  • BOLD has a Quick Ratio of 8.74. This indicates that BOLD is financially healthy and has no problem in meeting its short term obligations.
  • BOLD has a better Quick ratio (8.74) than 75.15% of its industry peers.
Industry RankSector Rank
Current Ratio 8.74
Quick Ratio 8.74
BOLD Yearly Current Assets VS Current LiabilitesBOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BOLD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 82.02% over the past year.
EPS 1Y (TTM)82.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BOLD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.76% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.34%
EPS Next 2Y22.41%
EPS Next 3Y16.03%
EPS Next 5Y7.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BOLD Yearly Revenue VS EstimatesBOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 50M 100M 150M 200M 250M
BOLD Yearly EPS VS EstimatesBOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. BOLD Valuation Analysis

4.1 Price/Earnings Ratio

  • BOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BOLD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLD Price Earnings VS Forward Price EarningsBOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLD Per share dataBOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • BOLD's earnings are expected to grow with 16.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.41%
EPS Next 3Y16.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BOLD Dividend Analysis

5.1 Amount

  • BOLD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOLD Fundamentals: All Metrics, Ratios and Statistics

BOUNDLESS BIO INC

NASDAQ:BOLD (4/30/2026, 2:19:09 PM)

1.47

+0.02 (+1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)03-09
Earnings (Next)05-18
Inst Owners51.46%
Inst Owner Change0.12%
Ins Owners3.03%
Ins Owner Change0%
Market Cap32.94M
Revenue(TTM)N/A
Net Income(TTM)-58.20M
Analysts45.71
Price Target4.08 (177.55%)
Short Float %0.73%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.85%
Min EPS beat(2)-9.35%
Max EPS beat(2)-4.35%
EPS beat(4)1
Avg EPS beat(4)-3.5%
Min EPS beat(4)-9.35%
Max EPS beat(4)5.3%
EPS beat(8)4
Avg EPS beat(8)-260.96%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)33.33%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.29%
EPS NY rev (1m)-13.95%
EPS NY rev (3m)-13.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-2.61
EYN/A
EPS(NY)-2.44
Fwd EYN/A
FCF(TTM)-2.11
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS4.4
TBVpS4.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -37.05%
ROE -58.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.59%
ROA(5y)-37.74%
ROE(3y)-47.8%
ROE(5y)-47.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.74
Quick Ratio 8.74
Altman-Z -2.57
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)114.44%
Cap/Depr(5y)150.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.62%
EPS Next Y6.34%
EPS Next 2Y22.41%
EPS Next 3Y16.03%
EPS Next 5Y7.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.45%
EBIT Next 3Y-10.97%
EBIT Next 5YN/A
FCF growth 1Y25.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.31%
OCF growth 3YN/A
OCF growth 5YN/A

BOUNDLESS BIO INC / BOLD Fundamental Analysis FAQ

What is the fundamental rating for BOLD stock?

ChartMill assigns a fundamental rating of 3 / 10 to BOLD.


What is the valuation status of BOUNDLESS BIO INC (BOLD) stock?

ChartMill assigns a valuation rating of 0 / 10 to BOUNDLESS BIO INC (BOLD). This can be considered as Overvalued.


How profitable is BOUNDLESS BIO INC (BOLD) stock?

BOUNDLESS BIO INC (BOLD) has a profitability rating of 1 / 10.


Can you provide the financial health for BOLD stock?

The financial health rating of BOUNDLESS BIO INC (BOLD) is 7 / 10.


Can you provide the expected EPS growth for BOLD stock?

The Earnings per Share (EPS) of BOUNDLESS BIO INC (BOLD) is expected to grow by 6.34% in the next year.